comparemela.com

Latest Breaking News On - Lipid rich necrotic core - Page 1 : comparemela.com

Heart Disease AI Software Maker Scores $27M

Euclid's AI-backed heart disease diagnosis software is designed to discern plaque changes in heart tissue when compared to specimen histopathology.

VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Presented as Late-Breaking Science at ESC Preventive Cardiology 2021

Message : Required fields Study quantified coronary plaque changes in patients administered 4 g/day of VASCEPA® (icosapent ethyl) on top of statin therapy Effect on coronary plaque stabilization reported to be significant at 9 months and sustained at 18 months DUBLIN, Ireland and BRIDGEWATER, N.J., April 17, 2021 (GLOBE NEWSWIRE) Amarin Corporation plc (NASDAQ:AMRN) today announced that further analyses from the Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides on Statin Therapy: EVAPORATE Trial were presented as Late-Breaking Science at European Society of Cardiology (ESC) Preventive Cardiology 2021, the Annual Congress of the European Association of Preventive Cardiology, on April 17, 2021, 3:50 PM CEST (Central European Summer Time) by Andrew Buckler, Founder and CTO of Elucid. As previously reported and published in the

Elucid Presents Results of the EVAPORATE Study at ESC Preventive Cardiology 2021 Late Breakers

Elucid Presents Results of the EVAPORATE Study at ESC Preventive Cardiology 2021 Late Breakers Elucid Software Quantifies Plaque Morphology to Enable Better Assessment of IPE Treatment Effects Elucid, a medical technology company developing AI software for physicians to optimize the treatment of patients with known or suspected vascular disease, announced that first author and Elucid founder Andrew Buckler presented findings today from the EVAPORATE (Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin Therapy, ClinicalTrials.gov Identifier: NCT02926027) study at the live session Late-Breaking Science: be the first to know! for ESC Preventive Cardiology 2021. The presentation, entitled

Study Confirms Elucids AI Software Accurately Estimates Lesion-Specific Ischemia Compared to Standard of Care

Posted on 314 Elucid, a medical technology company developing AI software to enable cardiovascular disease detection, announced today the publication of new clinical data in the International Journal of Cardiology. The study, entitled “Coronary plaque assessment of Vasodilative capacity by CT angiography effectively estimates fractional flow reserve” demonstrates that Fractional Flow Reserve (FFR) assessment derived from non-invasive plaque morphology using Elucid’s software is highly accurate as compared to invasive FFR. The team at Medical University of South Carolina (MUSC), led by Akos Varga-Szemes, MD and Joseph Schoepf, MD showed that Elucid’s AI software can quantitate both vessel structure and histologically-validated plaque composition from a routine CT angiography (CTA). These measurements were fed into Elucid’s computational neural networks to accurately estimate ischemia.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.